StockGuide AI
Track Stocks
EN RU ES
Compass Pathways

Compass Pathways

Price: 11.03

Company and Business Model

Compass Pathways is a healthcare company focused on developing innovative therapies for mental health conditions. Its core product is psilocybin therapy, aimed at treating treatment-resistant depression and other mental health disorders. The company operates primarily in the biotechnology segment, with revenue sources stemming from research and development collaborations, clinical trials, and potential future product sales.

Investment Profile

The investment profile of Compass Pathways is more aligned with growth investors, given its focus on innovative therapies and potential market expansion. The company currently does not offer dividends, and its financial metrics indicate a higher risk profile. Investors may consider the stock for its long-term growth potential, while being aware of the inherent volatility and uncertainties in the biotech sector.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
-2.15 Risk
EPS surprise
33.3% better than expected
20d volatility
6.1% normal
FMP / FinFeed data updated: 2026-06-06

Forecast impact

positive
Target Raised · Maxim Group · valid until 2026-06-14 · updated 2026-06-11
Target +81.3% target fill 55.1%
Reaction D5 +4.28% · D10 +16.10% fresh confirmed · market trust
Impact Potential +6 · Risk -3 up to 30 days or until target is reached
Reco: Hold Potential: 60 Risk: 66 Updated: 2026-06-11 05:16
How recommendation works
Why AI thinks so:
Weak fundamentals and high volatility raise concerns.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-09 02:36 Buy Hold High risk with uncertain fundamentals and negative momentum.
2026-06-03 02:37 Hold Buy High volatility; uncertain fundamentals warrant caution.
2026-05-08 15:32 — Hold High volatility with negative earnings and uncertain fundamentals.
Analyst forecasts
Date Analyst Action Target Price Then
2026-05-15 12:45 Maxim Group Target Raised 12 → 20 10.3956
2026-05-14 12:07 Morgan Stanley Target Raised 16 → 17 10.94
2026-05-07 14:26 UBS Update — → 18 9.2637
Atai Life Sciences Compass Pathways

Исполнительный указ президента США Дональда Трампа о психоделиках может ускорить реформу каннабиса

04/20/2026, 06:34 PM business announcement pharma Atai Life Sciences Compass Pathways
В минувшие выходные президент Дональд Трамп подписал указ, который ускоряет исследования психоделиков, таких как псилоцибин, MDMA и ибогаин.
Atai Life Sciences Definium Therapeutics Compass Pathways

Аналитики Oppenheimer ожидают роста акций компаний AtaiBeckley (ATAI), Compass Pathways (CMPS) и Definium Therapeutics (DFTX) после указа Трампа о психоделиках

04/20/2026, 04:35 PM investing review Аналитики: Oppenheimer pharma healthcare Atai Life Sciences Definium Therapeutics Compass Pathways
Недавний указ президента Дональда Трампа о применении психоделических препаратов для лечения психических заболеваний может привести к росту акций компаний в этом секторе, согласно аналитикам Oppenheimer.
APA Corporation TopBuild Compass Pathways Marvell Technology Carnival Corporation Royal Caribbean ConocoPhillips American Airlines Broadcom AST SpaceMobile

Акции American Airlines (AAL), Marvell Technology (MRVL) и других компаний демонстрируют значительные изменения на предрынке

04/20/2026, 12:33 PM business review finance internet APA Corporation TopBuild Compass Pathways Marvell Technology Carnival Corporation Royal Caribbean ConocoPhillips American Airlines Broadcom AST SpaceMobile
В преддверии открытия торгов на фондовом рынке наблюдаются значительные колебания акций различных компаний.